AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 16, 2026 2026 Earnings Call CORPORATE Headline · Source: SEC filing
Nasdaq: $CRMDDefenCath reimbursementREZZAYO reviewHeron asset purchaseCommercial execution risk

CRMD Stock Hub: CorMedix News, DefenCath and REZZAYO Review

CorMedix agreed to acquire Heron Therapeutics’ products for $145M in cash plus 14,583,333 shares. The deal would add four commercial brands and roughly $150M of trailing product revenue, with the cash price subject to customary purchase price adjustments. DefenCath pricing under the new dialysis rule, integration and the Q1 2027 REZZAYO review remain the tests. Third-quarter results on November 12 showed $54.5M of revenue and grant income, a $14.7M net loss and $3.1M of adjusted EBITDA; CorMedix kept its 2026 revenue guidance and suspended its previously issued 2027 DefenCath revenue guidance.

Last updated: November 18, 2026Financial period: quarter ended September 30, 2026 (unaudited results released November 12, 2026); common shares November 9 (Form 10-Q cover), plus 14,583,333 to be issued for the Heron purchaseFull research report (PDF): November 18, 2026; currency: USD
Latest development · next dated window
Closing of the Heron asset purchase · expected in the first quarter of 2027

CorMedix agreed to acquire substantially all of Heron Therapeutics’ assets for $145 million in cash plus 14,583,333 CorMedix shares, plus up to $55 million of earn-outs and a 5% royalty. The boards approved the deal unanimously; it needs Heron stockholder approval and antitrust clearance and is not subject to a financing contingency. Joint company release, November 9, 2026

CorMedix held a conference call and webcast on the transaction on November 9, 2026; the transcript and the investor presentation were furnished on Form 8-K on November 10. With its third-quarter results on November 12, 2026, CorMedix said it still anticipates closing in the first quarter of 2027, subject to Heron stockholder approval, regulatory clearance and other customary conditions. Company release, Form 8-K exhibit 99.1 · Q3 2026 results · Form 8-K, November 10, 2026
Full research report · PDF
CorMedix Inc. ($CRMD), research updated November 18, 2026
19 pages covering the November 12, 2026 third-quarter results and the suspended 2027 DefenCath outlook, the call transcript furnished on November 16 with the slower DefenCath total parenteral nutrition (TPN) study enrollment and the pending Medicare Advantage contracting, the $8.32 post-TDAPA (transitional drug add-on payment adjustment) add-on from the first quarter of 2027, the September 30 cash and nine-month operating cash flow, the November 9, 2026 agreement to buy substantially all of Heron Therapeutics’ assets, the REZZAYO prophylaxis target action, capital structure, risks, sources and FAQ. This is dated research; the hub follows later developments. For personal use only: redistribution prohibited.
Get the report (PDF)
Next company windows · earnings and regulatory dates
Deal closing Q1 2027; REZZAYO target action Q1 2027; 2027 DefenCath guidance deferred to early 2027

CorMedix released third-quarter 2026 results on November 12, and held a corporate-update call that day. It suspended its previously issued 2027 DefenCath revenue guidance after CMS reimbursement changes and expects to give new guidance in early 2027 (Q3 2026 results). The September presentation places additional ReSPECT data in Q4 2026 and DefenCath real-world results in November; these are company windows, without an exact release day. Source: company update, SEC

The FDA accepted the REZZAYO prophylaxis sNDA with Priority Review and a Q1 2027 target action window. Acceptance is not approval. Source: company announcement
CorMedix Inc. CRMD daily stock chart
Daily chart $CRMD. The chart link is an affiliate link. Interactive chart with bull and bear scenarios on JC Just Charts →

CRMD stock at a glance

Chart analysis · JC
Technical chart analysis of $CRMD with bull and bear scenarios on JC Just Charts.
Cash · September 30, 2026 (unaudited)
$355.2M
Cash and cash equivalents excluding restricted cash, in the third-quarter results of November 12; nine-month operating cash flow $218.3M. At December 31, 2025 the filing showed $144.837M. Source: SEC
Q3 2026 results
$54.5M
Revenue and grant income, including $17.2M of DefenCath net sales; net loss $14.7M ($0.19 per share); adjusted EBITDA $3.1M, a non-GAAP measure. Q3 2025: $104.3M. Source: SEC
Heron upfront consideration
$145M + shares
$145M in cash plus 14,583,333 shares. Up to $55M of earn-outs and a 5% royalty follow. Company release
Convertible principal · September 30
$150M
Principal due August 1, 2030; distinct from its accounting carrying amount. Source: SEC
Pharmakon term loan · signed November 9
$150M
Senior secured facility; $75M drawn at the deal closing and a second tranche of up to $75M, for acquisitions or in-licensing of commercial-stage products, to be drawn before June 30, 2028. Company release
Basic common shares · November 9
79.538M
79,537,626 shares on the third-quarter Form 10-Q cover, against 77,944,324 at August 10; a dated common-share count rather than fully diluted capitalization. Source: SEC
2026 revenue outlook
$325–345M
Consolidated revenue guidance maintained on November 12; adjusted EBITDA guidance narrowed to $130–140M and cash-based OpEx guidance lowered to $140–145M. Previously issued 2027 DefenCath revenue guidance suspended. Source: SEC If the Heron acquisition closes, the company estimates combined 2026 pro forma revenue of $465–490M, with Heron’s assets estimated at $125–150M of revenue in 2027. Company release

Where CorMedix Inc. stands now

CorMedix markets infection-focused products, led by DefenCath, with REZZAYO and the acquired Melinta portfolio broadening its commercial base. First-half 2026 operations generated cash and profit, but dialysis reimbursement changed July 1, and the next operating test is volume, collections and margins under the new pricing. Source: SEC

On November 9, 2026 CorMedix agreed to buy substantially all of Heron Therapeutics’ assets: four commercial products (ZYNRELEF, APONVIE, CINVANTI and SUSTOL) with approximately $150 million of trailing twelve-month net product revenue, for $145 million in cash plus 14,583,333 shares, up to $55 million of earn-outs and a 5% royalty on qualifying sales above $25 million in 2027–2029. The company expects $45–60 million of annual cost synergies by the end of 2027 and pro forma 2026 revenue of $465–490 million, and will draw $75 million of a new $150 million Pharmakon term loan at closing. Joint company release

Third-quarter 2026 results, released November 12, were the first full quarter after DefenCath’s move to the post-TDAPA period on July 1. Revenue and grant income fell to $54.5 million from $104.3 million a year earlier: DefenCath contributed $17.2 million, helped by a $5.0 million favorable change in an estimate of sales allowances, and the rest of the portfolio $37.3 million. The net loss was $14.7 million, or $0.19 per share, including $11.5 million of non-cash expense from remeasuring Melinta contingent consideration; adjusted EBITDA, a non-GAAP measure, was $3.1 million. CorMedix kept 2026 revenue guidance of $325–345 million, narrowed adjusted EBITDA guidance to $130–140 million, lowered cash-based OpEx guidance to $140–145 million and suspended its previously issued 2027 DefenCath revenue guidance, citing CMS reimbursement changes; it expects to update that outlook in early 2027. Q3 2026 results

One transaction now carries both the growth case and the balance-sheet risk.

CorMedix pays $145 million of cash and issues about 18% more shares while adding $75 million of secured debt, before any Heron revenue is integrated or the $45–60 million of synergies is delivered. The deal also needs Heron stockholder approval and antitrust clearance, and is expected to close in the first quarter of 2027.

The constructive case

Four approved brands with roughly $150 million of trailing revenue move onto a commercial platform CorMedix already runs in hospitals, surgery centers and infusion suites, where it expects $45–60 million of synergies and immediate accretion to earnings and free cash flow. The Pharmakon facility provides $75 million of the $145 million cash consideration with no financing contingency, and leaves a second tranche of up to $75 million, reserved for acquisitions or in-licensing of commercial-stage products, to be drawn before June 30, 2028.

The cautious case

The purchase is paid for with cash that also has to absorb the 2027 dialysis-pricing reset, and with a fixed 14,583,333 new shares, about 18% of the 79,537,626 shares outstanding at November 9, whatever the share price before closing. Integration, retention of Heron’s products and the earn-out thresholds all have to be delivered, and the deal does not close before the first quarter of 2027.

Latest CorMedix Inc. news

Nov 16, 2026

CorMedix Q3 2026 Earnings Call: Revenue, Heron Acquisition, Guidance

CorMedix reported third quarter 2026 revenue of $54.5 million, adjusted EBITDA of $3.1 million and $355 million in cash. It reaffirmed full year 2026 revenue guidance of $325 million to $345 million and narrowed adjusted EBITDA guidance to $130 million to $140 million. It agreed to acquire substantially all assets of Heron Therapeutics, with closing anticipated in the first quarter of 2027. DefenCath 2027 guidance was deferred to early 2027.

Nov 13, 2026

Oppenheimer lowers CorMedix price target to $13 from $15

Oppenheimer reduced its price target on CorMedix to $13 from $15. Analyst action reported by the press; it is the bank's view, not Merlintrader's.

Nov 13, 2026

RBC Capital lowers CorMedix price target to $14 from $15, maintains Outperform rating

RBC Capital reduced its price target on CorMedix to $14 from $15. The bank kept its Outperform rating. Analyst action reported by the press; it is the bank's view, not Merlintrader's.

Nov 13, 2026

Needham lowers CorMedix price target to $12, keeps Buy rating

Needham reduced its price target on CorMedix to $12 from $14. The firm maintained its Buy rating. Analyst action reported by the press; it is the bank's view, not Merlintrader's.

Nov 12, 2026

CorMedix reports third quarter 2026 financial results and provides business update

CorMedix reported third quarter 2026 consolidated revenue of $54.5 million, a net loss of $14.7 million, and adjusted EBITDA of $3.1 million. DefenCath sales were $17.2 million, and the remaining portfolio contributed $37.3 million. The company maintains full-year 2026 consolidated revenue guidance of $325 to $345 million and narrows adjusted EBITDA guidance to $130 to $140 million. Cash and short-term investments, excluding restricted cash, totaled $355.2 million at September 30, 2026.

Nov 10, 2026

RBC Capital lifts CorMedix price target to $15 from $14

RBC Capital raised its price target on CorMedix to $15 from $14 and kept its Outperform rating. Analyst action reported by the press; it is the bank's view, not Merlintrader's.

CRMD stock catalysts and company windows

  • November 9, 2026 · held — CorMedix conference call and webcast on the Heron asset purchase; transcript and investor presentation furnished on Form 8-K on November 10 (transcript, presentation). Company release
  • November 12, 2026 — Third-quarter 2026 results released, with a corporate-update call that day: revenue and grant income $54.5 million, net loss $14.7 million, adjusted EBITDA $3.1 million; 2027 DefenCath revenue guidance suspended. Reported · results release
  • First quarter of 2027 · expected — Closing of the Heron asset purchase, subject to Heron stockholder approval and antitrust clearance. Company announcement
  • Q4 2026 — Additional ReSPECT data, according to the September corporate presentation. Company window
  • November 2026 — DefenCath two-year real-world results, per the September corporate presentation; the company has not announced a date. Company window
  • By year-end 2026 — Possible update on DefenCath Medicare Advantage contracting: on the November 12 call CEO Joseph Todisco said he was cautiously optimistic about reaching an agreement before the end of the year (call transcript). Management expectation, no agreement announced
  • Before the next quarterly call — Decision on the strategy for the DefenCath TPN Phase 3 study: on November 12 management said enrollment was tracking meaningfully behind the original timelines and that it is evaluating alternative paths to approval with the FDA if enrollment does not accelerate in the next one to two months. The September presentation had placed TPN data in 2028 (call transcript). Company decision pending
  • Q1 2027 — DefenCath post-TDAPA add-on of $8.32 per dialysis session under the CMS final rule of October 28, 2026 (current: $2.37), followed by a new quarterly adjustment process. Reimbursement schedule
  • Q1 2027 — FDA target action window for the REZZAYO prophylaxis supplemental application. Regulatory review; not approval
  • Early 2027 — New 2027 DefenCath outlook, after the suspension of the previously issued 2027 revenue guidance on November 12, 2026. Company expectation

Company update, November 2; Company presentation; FDA acceptance announcement

DefenCath pricing and CorMedix cash generation

Q2 revenue and grant income were $101.931M, operating income $42.910M and net income $25.988M. H1 operating cash flow was $128.619M. These dated figures predate the July 1 reimbursement change.

The third-quarter results of November 12 put cash and cash equivalents at $355.150 million at September 30, 2026, excluding restricted cash, against $256.692 million at June 30; cash, equivalents and restricted cash totaled $356.138 million. Nine-month operating cash flow was $218.318 million, helped by working-capital movements including the timing of rebate payments, and nine-month net income was $49.867 million. Total liabilities were $456.039 million. CorMedix says it has sufficient resources to fund operations for at least twelve months from the issuance of its Form 10-Q. Q3 2026 results, Form 8-K exhibit 99.1 · Q3 2026 Form 10-Q, filed November 12

The Heron transaction changes the scale on both sides of the balance sheet. On the company’s own estimates the combined business would have reported 2026 revenue of $465–490 million, against the $325–345 million CorMedix still guides to on its own, and Heron’s assets would add $125–150 million of revenue in 2027. The price is $145 million of cash, 14,583,333 shares, up to $55 million of ZYNRELEF earn-outs and a 5% royalty above $25 million of qualifying sales in 2027–2029, with $75 million drawn on a new Pharmakon facility at closing and a second tranche of up to $75 million, reserved for acquisitions or in-licensing of commercial-stage products, to be drawn before June 30, 2028. Joint company release, November 9, 2026 Source: company update, SEC

CorMedix deep dive: the full analysis

The chapters below go through the company in detail: 01 scenarios: the reimbursement reset and the next growth leg; what would falsify this reading; 02 a commercial business with two different earnings engines; 03 what the June quarter says, and what it cannot show; 04 DefenCath reimbursement is the central commercial catalyst; 05 clinical evidence behind adoption, and the limit of contracts; 06 REZZAYO: positive prophylaxis data, then regulatory execution; 07 cash generation is real, but reported cash is not all future flexibility; 08 debt and success-related obligations compete for cash; 09 shares, buybacks and future issuance capacity; 10 short interest, large holders and insider transactions; 11 profit quality and the portfolio’s operational risks; 12 what to watch next, and the investment question. Every figure carries its date and its primary source. The same research is available as a downloadable PDF in the Merlintrader Research Library: Biotech.

01 Scenarios: the reimbursement reset and the next growth leg

Bull case — cash survives the lower-price period

If DefenCath keeps its patients while pricing adjusts to the new reimbursement system, CorMedix could emerge with a more durable business than the headline sales decline suggests. The constructive case would combine continued cash generation, broader dialysis adoption, stronger contribution from the Melinta products and a credible regulatory path for REZZAYO prophylaxis. The September 2026 presentation places expected additional ReSPECT data in the fourth quarter and two-year DefenCath real-world data in November. Those are evidence windows, not automatic revenue events. Source The November 9, 2026 agreement to buy Heron’s four commercial products adds an established revenue base of approximately $150 million of trailing twelve-month net product revenue at September 30 and company-estimated synergies of $45–60 million by the end of 2027, which would broaden the business beyond DefenCath. The transaction is signed, not closed. Source

The balance sheet would help finance that transition if management preserves genuinely available cash. CorMedix reported $355.150 million of cash and equivalents at September 30, 2026 and generated $218.318 million from operating activities in the nine months. Those figures provide room to operate, but subsequent cash collateral and product milestones matter. A positive interpretation needs post-transition receipts and margins, not simply a repeat of a large reported cash number. Source

Base case — a profitable company with an uneven second half

If the lower DefenCath price reduces revenue as anticipated, the company could remain profitable while reporting a much weaker sales run rate than in the first half. The outlook kept in November is $325–345 million of consolidated 2026 revenue, and $283.877 million was already recognized in the nine months to September 30, 2026. A calculated $41.123–61.123 million (Merlintrader calculation) remains for the fourth quarter alone. A sequential decline can therefore coexist with delivery of management’s annual plan. Source Source

Under this scenario, regulatory clarification and fuller clinical data would arrive in stages. The September presentation retained a third-quarter sNDA submission target for REZZAYO; that window has ended. On October 19, 2026 the company announced that the FDA accepted the filing with Priority Review and a PDUFA target action date in the first quarter of 2027; a target action date is not an approval. Source Source

Bear case — the reset damages adoption as well as price

If reimbursement pressure leads dialysis customers to narrow use, revenue could fall for both price and volume reasons. A slower REZZAYO regulatory path, weaker acquired-product sales or higher commercial costs could then reduce cash generation together. The September 30, 2026 filing discloses a first letter of credit of approximately $85 million, to be established in the fourth quarter of 2026 and backed by an equal amount of cash in a collateral account classified as restricted. Restricted collateral would reduce flexibility even though the corresponding customer rebate payment was deferred. Source The same agreement commits $145 million of cash, 14,583,333 new shares and $75 million drawn on a secured facility before any Heron revenue or synergy arrives; if the acquired brands erode or integration costs more than estimated, leverage rises while the DefenCath price reset is still working through. Source

The bearish case would become stronger if management cut the annual outlook, if underlying collections deteriorated or if full ReSPECT results weakened the preliminary clinical interpretation. It would become weaker if demand remained durable under the new economics and cash generation covered development, debt service and contractual milestones. Short interest can intensify either market response; it does not decide which business outcome occurs.

What Would Falsify This Reading

This reading depends on durable product use, cash that remains deployable, and a regulatory process that advances beyond company targets.

  • Commercial demand weakens. If the reimbursement change reduces patient use as well as net price, the assumption that this is mainly a pricing transition would fail. The June report anticipates a lower-price second half; it does not guarantee stable demand. Source
  • Liquidity becomes less flexible. If restricted cash and rebate settlements absorb more resources than operations replenish, the reported cash balance would overstate practical flexibility. The first letter of credit, approximately $85 million in the fourth quarter of 2026, requires equal cash collateral. Source
  • Clinical and regulatory progress diverge. If fuller ReSPECT results weaken the tolerability proposition or the application timeline moves out, positive topline data would not by themselves support the launch expectations. The Q1 2027 PDUFA target date is not an approval. Source Source
  • A stronger outcome also changes the reading. Durable use at the new price, solid collections and a clear FDA review timetable would reduce the transition risk. The September company windows provide specific evidence to follow. Source

These are observations that would weaken the interpretation, not forecasts of inevitable events.

02 A commercial business with two different earnings engines

CorMedix sells medicines into dialysis facilities, hospitals and related treatment settings. DefenCath is its largest product. It is a catheter lock combining taurolidine and heparin, intended to reduce catheter-related bloodstream infections in adults receiving chronic hemodialysis through a central venous catheter. The 2025 annual report describes its inpatient and outpatient commercial launches in 2024. It is an approved commercial product, not a pending first approval. Source

The acquisition of Melinta on August 29, 2025 added REZZAYO, MINOCIN, VABOMERE, KIMYRSA, ORBACTIV and BAXDELA, together with the cardiovascular brand TOPROL-XL. The commercial logic is to sell more products through an institutional infrastructure that already reaches relevant customers. The economic test is whether that broader portfolio contributes enough profit and cash to reduce dependence on a single reimbursement-sensitive product. Counting brands alone does not answer it. Source

For the quarter ended June 30, 2026, DefenCath provided $66.119 million of product sales. Melinta contributed $28.222 million of product sales, with a further $4.966 million of contract revenue and $2.624 million of grant income. Together those latter categories explain the approximately $35.8 million Melinta contribution described in the earnings announcement. Treating all of it as medicine sold to patients would exaggerate the repeatable product-sales base. Source Source

This distinction also matters when comparing quarters. A royalty, contract milestone or reimbursement of development spending can support cash and economics without behaving like recurring product demand. The useful dashboard separates DefenCath use, net realized pricing, acquired-product sales and other revenue. It then asks whether the combined business covers its expenses after temporary accounting benefits and transaction effects are considered.

03 What the June quarter says, and what it cannot show

Total revenue and grant income were $101.931 million in the second quarter of 2026, against $127.427 million calculated for the first quarter from the half-year total. The sequential fall was $25.496 million, approximately 20%. DefenCath more than accounted for that change: $66.119 million in the second quarter versus $97.511 million in the first. These are financial-period comparisons, not a description of the stock’s performance. Source

The first-quarter DefenCath figure benefited from a $9.0 million favorable revision of estimated Medicaid rebates and product returns. Removing that disclosed benefit gives a calculated first-quarter comparison of approximately $88.511 million; the second-quarter figure is still lower, but the gap is smaller. The whole reported decline cannot be attributed to fewer patients or lower unit demand. The company also describes customer purchasing patterns and lower wholesaler inventory for the acquired portfolio. Source

Year-over-year growth needs similar care. The second quarter of 2025 had no Melinta contribution because the acquisition had not closed. The second-quarter 2026 consolidated increase therefore mixes DefenCath growth with a larger corporate perimeter. This does not make the increase artificial, but it changes what it demonstrates. For organic execution, product-level demand and comparable customer cohorts are more informative than the consolidated growth percentage. Source

The quarter ended before the July reimbursement transition. Its margins and cash receipts provide a starting point, not proof of the economics after that change. The third quarter, reported on November 12, 2026, was the first reporting period after the change: revenue and grant income were $54.519 million and DefenCath sales $17.181 million, so the interaction of price, patient use, customer inventory and rebates is now visible in the filed numbers. A lower revenue quarter consistent with the annual plan would mean something different from a lower quarter caused by lost customers and a reduced outlook.

A practical way to read the next earnings release is to rebuild the revenue bridge before comparing EPS. First separate DefenCath from the acquired portfolio, then split acquired-product sales from contract and grant income. This avoids interpreting every dollar of consolidated growth as another patient prescription. The next step is to compare gross sales adjustments with the net revenue actually recorded. A rebate estimate can change recognized sales without an equal change in current treatment volume, and wholesaler purchases can differ from use at the facility. Finally compare those operating movements with the annual guidance range. A quarter can look weak against its immediate predecessor while remaining consistent with a deliberately lower second-half plan. SEC filing

The same discipline applies to profitability. Using the reported June-quarter amounts, the operating margin is approximately 42.1%, calculated as $42.910 million divided by $101.931 million. Net margin is approximately 25.5%, using $25.988 million as the numerator. The difference is meaningful: other income and expense and income taxes sit between the operating business and the bottom line. Neither percentage is a forecast under the new reimbursement arrangement. These historical margins provide a comparison point for the next release, while the explanations for any change matter more than preserving a particular percentage. SEC filing

For an illustrative revenue sensitivity, a ten-percent difference in quarterly DefenCath net sales relative to the reported $66.119 million would be $6.612 million. That is arithmetic, not an estimate of a future miss or beat. It would not translate dollar for dollar into operating income because manufacturing costs, royalties, sales adjustments and other expenses can move with sales. A model that mechanically subtracts the full amount from profit would be making an additional contribution-margin assumption. Stating that assumption explicitly prevents a simple sensitivity from masquerading as management guidance. SEC filing

04 DefenCath reimbursement is the central commercial catalyst

On July 1, 2026, DefenCath moved from its initial TDAPA reimbursement period into the post-TDAPA add-on adjustment. CorMedix’s August financial report says the payment reduction to dialysis providers should translate into lower net pricing and lower DefenCath sales in the second half. The transition has happened; the remaining question is how well the business performs under it. Source

The distinction between provider payment and manufacturer revenue is essential. Medicare pays the facility under a reimbursement framework. CorMedix negotiates its own commercial terms, and the customer’s economics influence willingness to use the product. An increase in a payment adjustment is therefore not a one-for-one increase in CorMedix’s price, nor does it guarantee patient adoption.

The June 26, 2026 proposed CMS rule estimated a DefenCath post-TDAPA component of $5.5951 for 2027, compared with the finalized $2.3710 component for the third and fourth quarters of 2026. Those are payment-adjustment components, not prices per vial or checks paid to CorMedix. On October 28, 2026 CMS released the 2027 end-stage renal disease prospective payment final rule, which set a post-TDAPA add-on for DefenCath of $8.32 per dialysis session for the first quarter of 2027, within the company’s previously guided range of three to five times the current $2.37, together with a new quarterly process for calculating the adjustment. CorMedix said third-party projections, including those of a large dialysis organization, are not guidance it provides or endorses, and that actual quarterly rates depend on how CMS applies utilization data. Source November 2 business update

The September company presentation gave a DefenCath revenue outlook of $175–195 million for 2026 and $100–140 million for 2027; the company suspended any previously issued 2027 DefenCath guidance on November 12, 2026. DefenCath sales were $180.811 million in the nine months to September 30, 2026, so the remaining part of that September range is at most $14.2 million if the top end is reached (Merlintrader calculation), and the fourth quarter carries most of the uncertainty after the reimbursement change. Source Source

Medicare Advantage agreements and inpatient use can change the customer mix, but they need actual commercial terms and utilization to become meaningful offsets. For a trader, the useful catalyst is the combination of the final reimbursement framework, customer adoption and management’s updated revenue bridge. A favorable rule headline with weak commercial conversion would be an incomplete improvement.

05 Clinical evidence behind adoption, and the limit of contracts

DefenCath has clinical evidence behind its commercial position. The November 2023 LOCK IT-100 publication analyzed 795 participants: 397 in the taurolidine/heparin group and 398 in the heparin control group. Catheter-related bloodstream infections occurred in 9 versus 32 participants. The hazard ratio was 0.29, with a 95% confidence interval of 0.14–0.62 and p<0.001, corresponding to a 71% reduction in infection risk. Safety was comparable; the study did not show a significant difference in catheter removal or loss of patency. Source

That evidence supports an infection-prevention proposition. It does not by itself tell us the price a payer will support or the size of a customer’s rollout. Clinical effectiveness, economic benefit and manufacturer revenue are connected through procurement and reimbursement decisions rather than through a guaranteed conversion formula.

In its September 2026 presentation, CorMedix reported an observational matched analysis with 7,051 patients in each cohort, showing a 72% reduction in infection incidence and a 70% reduction in annualized infection-related hospitalizations. Those are interim real-world findings presented by the company, distinct from the randomized trial. A retrospective comparison can be affected by differences in care and patient selection even after matching. The next two-year real-world data window is November 2026 in that presentation. Source

The August 13 announcement also reported a new multi-year agreement with a large dialysis operator, extending the contract footprint to all five leading U.S. dialysis providers. The new customer had started ordering and planned a third-quarter pilot. An agreement and initial orders are encouraging, but they do not amount to a full national rollout. The next meaningful commercial evidence is broader recurring use at acceptable net pricing, rather than the contract count alone. Source

06 REZZAYO: positive prophylaxis data, then regulatory execution

REZZAYO is an antifungal with an existing treatment indication. Its proposed prophylaxis expansion would address prevention of invasive fungal disease in adults undergoing allogeneic stem-cell transplantation. That is a separate commercial opportunity requiring an expanded approval. It is not already approved merely because the medicine is marketed for treatment. Source Source

On April 27, 2026, CorMedix reported that ReSPECT met its primary non-inferiority endpoint. Fungal-free survival at day 90 was 60.7% with rezafungin versus 59.0% with the standard regimen. The sponsor’s registry update of April 13 lists 602 actual participants. That enrollment count is not a substitute for the detailed analysis population behind each endpoint. The topline release does not provide a numerical p-value for this comparison; it reports the non-inferiority conclusion. A small numerical advantage is not the same as demonstrated superiority. Source Source

The company described comparable mortality and efficacy against the studied pathogens, with favorable findings in some tolerability-related secondary outcomes. Those are potentially useful clinical distinctions, but full data on discontinuations, adverse events and endpoint consistency will determine how persuasive the advantage is to clinicians. The September presentation expects additional prophylaxis data in the fourth quarter of 2026. Source Source

For the U.S. application, the August announcement and September presentation targeted submission in the third quarter. That is now a past target. On October 19, 2026 the company announced FDA acceptance of the application with Priority Review and a PDUFA target action date in the first quarter of 2027. Acceptance for review is not an approval. Source Source

CorMedix’s estimate of an opportunity exceeding $2 billion is an addressable-market estimate built from assumptions. It is not a sales forecast, a contracted order book or a value that accrues entirely to the company. Adoption, eligible patients, treatment duration, competition and royalties determine the revenue and cash ultimately retained. Source

07 Cash generation is real, but reported cash is not all future flexibility

Cash and cash equivalents were $355.150 million at September 30, 2026, excluding restricted cash, against $256.692 million at June 30, with nine-month operating cash flow of $218.318 million, per the third-quarter results; cash, equivalents and restricted cash totaled $356.138 million. Against that balance, the Heron purchase calls for $145 million in cash at closing and a $75 million draw on a new $150 million senior secured term loan, so the cash reported at September 30 is not the post-closing figure. Third-quarter release, November 12 Joint release

At June 30, 2026, cash and equivalents were $256.692 million, with no short-term investments on the balance sheet. Restricted cash was another $0.988 million, excluded from that available-cash figure. The broader wording “cash and short-term investments” used in the announcement therefore refers to a balance that was entirely cash and equivalents at that reporting date. The Talphera equity investment is a separate asset, not part of the cash balance. Source

Operating activities generated $218.318 million in the nine months ended September 30. Dividing by nine gives approximately $24.258 million of average monthly operating cash generation. After $3.203 million of purchases of property, plant and equipment in the same nine months, the calculated remainder was $215.115 million, or approximately $23.9 million per month. These are historical cash measures, not a forecast for the reimbursement-reset period. These historical positive cash flows do not provide a monthly cash-burn rate or a cash-exhaustion date. Source

Cash conversion benefited from collections and changes in liabilities, including a $10.013 million reduction in receivables and an $8.346 million increase in accrued expenses and other liabilities during the half year. Inventory and prepaid spending absorbed cash. The message is not that cash generation is illusory, but that the sustainable level must be judged after normal customer settlements and the new product pricing flow through. Source

A subsequent customer agreement deferred certain volume-rebate payments and required cash-backed letters of credit. The September 30, 2026 filing states that the agreement was concluded in the third quarter and that the first letter of credit, approximately $85 million, is to be established in the fourth quarter of 2026, with an equal amount of cash held in a collateral account classified as restricted. That collateral will reduce reported flexible cash when it is put in place. Source

Management’s statement that resources cover at least twelve months from the issuance of the third-quarter Form 10-Q is a funding assessment, and profitability can change. The next balance sheet should show actual restricted cash, receivable collections, rebate liabilities and operating cash flow together. A larger total cash number would be less useful if a growing portion could not be redeployed.

Cash and debt can be compared without pretending that the difference is fully distributable. September 30 cash and equivalents less $150 million of note principal equals $205.150 million (Merlintrader calculation). The $85 million of collateral planned for the fourth quarter and the $145 million of cash due at the Heron closing show how quickly that simple difference can shrink. The comparison deliberately ignores later operating receipts and payments, the timing of debt maturity and other obligations: it is a way to visualize competing claims on liquidity, not an assertion that the company should repay its notes immediately. SEC filing

The distinction between collateral and an expense also changes how to read the cash-flow statement. Posting cash to support a letter of credit can remove flexibility while leaving a cash asset on the balance sheet in a restricted category. Paying a customer rebate settles a liability and can produce a different cash-flow pattern. A reader should therefore compare unrestricted cash, restricted cash and the associated customer obligation rather than treating one line in isolation. Otherwise a deferral could look like permanently improved cash generation, or a restriction could be mistaken for an equivalent operating loss. The September 30 filing identifies the mechanism; the next filing must show what actually occurred. SEC filing

A useful cash bridge begins with September 30 unrestricted cash, adds subsequent operating cash flow, then subtracts investing and financing uses and identifies any transfers into restriction separately. This is a framework for reading the next report, not a forecast with missing inputs filled in. Share repurchases, employee tax withholding, investment movements and milestones can make the ending balance differ from a calculation based solely on reported net income. Positive historical operating cash flow is valuable precisely because it is measured after working-capital movements, but the timing of those movements still determines how reproducible the result is. SEC filing

08 Debt and success-related obligations compete for cash

On November 9, 2026 CorMedix signed a $150 million senior secured term loan facility with funds managed by Pharmakon Advisors, of which $75 million is drawn to support the Heron transaction and a second tranche of up to $75 million is reserved for acquisitions or in-licensing of commercial-stage products and must be drawn before June 30, 2028. The existing $150 million convertible principal due August 1, 2030 is unchanged. Rubric Capital Management, holder of Heron’s 2031 convertible notes, agreed to exchange $35.0 million of principal plus accrued interest (approximately $37.8 million in total at September 30, 2026) for CorMedix shares received by Heron, in four quarterly tranches after the closing. Joint release

CorMedix had $150 million principal of convertible notes outstanding at June 30, 2026. The coupon is 4%, and maturity is August 1, 2030. The $145.150 million balance-sheet carrying amount is lower because of unamortized financing costs; it does not reduce the principal obligation. The stated coupon implies approximately $6 million of annual contractual interest before any change in the notes. Source

The initial conversion rate is 74.2515 shares per $1,000 principal, corresponding to approximately $13.47 per share. At that initial rate, the full principal represents a calculated 11.138 million potential shares. Conversion conditions and the company’s choice of cash, shares or a combination matter. This is potential dilution, not stock already issued. The June report said early-conversion conditions had not been satisfied at that reporting date. Source

REZZAYO success would also bring payments. The June report describes a $30–40 million regulatory milestone under the Mundipharma licensing arrangement upon prophylaxis approval. Separately, former Melinta owners can receive up to $25 million tied to the pathogens included in an FDA-approved label by June 30, 2029: $20 million for Candida and $2.5 million each for Aspergillus and Pneumocystis. CorMedix may settle that separate acquisition milestone in cash or shares. Royalties also continue. Source

The contingent-consideration liability was $122.430 million at September 30, 2026 ($23.329 million current and $99.101 million long term), including longer-term royalty obligations valued using estimates. That accounting value is not all due immediately and should not be subtracted as if it were a single near-term cash invoice. Conversely, treating the successful launch opportunity as costless would omit real claims on future economics. Source

The capital structure also retains preferred-stock rights and restrictions described in the annual report. Cash exceeding note principal does not make the company debt-free or remove its financing restrictions. The relevant practical test is whether commercial receipts cover ordinary spending, coupon payments, collateral requirements and milestones while leaving capacity for development. Source Source

The two disclosed approval-related milestone arrangements should be evaluated independently before being combined. A $30–40 million licensing milestone and up to $25 million for the acquisition-related label milestone imply a maximum illustrative combined range of $55–65 million if the full second amount becomes payable. The actual label, contractual trigger and permitted form of payment matter. This is not a current invoice and does not mean both obligations will be settled on the same day. It shows why an approval can improve the commercial opportunity while also creating a funding and capital-allocation decision. SEC filing

If management elects to settle an eligible acquisition milestone in shares, the relevant denominator is the share count and price used under the agreement at that time. Dividing a hypothetical payment by a current market quote is merely a sensitivity; it cannot show the contractual number of shares or the eventual dilution. Cash settlement avoids that immediate issuance but consumes resources that could otherwise support launch activities or the reimbursement transition. There is no universally superior choice independent of valuation, liquidity and expected returns. Until a disclosure states the actual election and its terms, neither outcome is settled. SEC filing

09 Shares, buybacks and future issuance capacity

The Heron purchase adds 14,583,333 CorMedix shares to the 79,537,626 outstanding at November 9, 2026, an increase of about 18 percent. The number is fixed, calculated as $105 million divided by $7.20 per share, and is not adjusted for the share price before closing. Joint release

The reported common-share count was 79,537,626 on November 9, 2026, compared with 79,477,190 at September 30, 2026. Neither a rounded count nor diluted earnings-per-share shares replaces that dated outstanding-share disclosure. The balance sheet authorized 160 million common shares and 2 million preferred shares at September 30. Authorized capacity is permission to issue, not an issuance that has happened. Source

CorMedix repurchased and retired approximately 2.403 million common shares for $17.484 million during the nine months ended September 30, 2026, none of them in the third quarter. Against the $75 million authorization running through December 31, 2027, approximately $57.516 million remained at September 30 (Merlintrader calculation). The program is discretionary and may be suspended. It provides a possible offset to dilution, but no fixed future buyer or price floor. Source

At September 30, 2026, 4,110,810 restricted and performance stock units remained outstanding. The 2025 annual report separately reported 4,521,821 options outstanding at year-end; that historical option count is not a current total after subsequent exercises. The company issued no new options in the nine months, while grants and vesting of stock units remained relevant. Compensation-related issuance can continue even during a buyback program. Source Source

The September 30 filing lists $11.6 million remaining under the ATM sales agreement and $15.0 million remaining under the shelf registration. Those are overlapping layers of financing capacity, not $26.6 million of additive cash. In the third quarter CorMedix sold approximately 1.3 million shares under the ATM program for net proceeds of approximately $10.1 million; no ATM proceeds were reported in the first half of 2026. Remaining capacity means management can consider further equity funding; it does not show that cash is urgently required. Source

The compensation framework uses approved share reserves. Those reserves and any future plan changes belong alongside awards, preferred conversions and the convertible notes when assessing dilution. A fully diluted estimate counts each award once, not through both its reserve and its outstanding grant. For trading purposes, actual common shares, new financing terms and the choice of cash versus shares for milestones are the decisive changes.

10 Short interest, large holders and insider transactions

Short interest and ownership change with every settlement and filing, so the dated disclosures are the reference: the reported share count is the one on the cover of the latest Form 10-Q, the ownership positions are the 13G and 13G/A filings quoted below, and the short-interest settlements from Nasdaq carry their own dates. The chart carries the price history.

Named ownership filings provide another view. Deep Track reported 6,274,076 shares, or 7.94%, as of March 31, 2026 in its May filing. Shaibatalhamd Aymen Abdalkader reported 4,618,511 shares, approximately 5.9%, for June 11 in the June filing. These are dated holdings, not commitments to retain positions or participate in future funding. These holdings alone do not yield a reliable tradable float. Source Source

Recent insider entries also need classification. Janet Dillione received 48,909 common shares on September 18 through settlement of deferred phantom compensation following termination of the directors’ plan. That was not an open-market purchase. Susan Blum’s August 29 disposition of 8,424 shares was coded as tax withholding in her September 1 filing, rather than a discretionary market sale. Neither transaction supports a simple “management buying” or “management selling” narrative. Source Source

11 Profit quality and the portfolio’s operational risks

Second-quarter 2026 GAAP operating income was $42.910 million and net income $25.988 million. Adjusted EBITDA was $58.7 million in the August announcement. The measures answer different questions: EBITDA adjustments remove items such as amortization and share compensation, while cash flow also depends on collections and settlement timing. The adjusted figure cannot substitute for cash available to shareholders. Source Source

General and administrative expense benefited from $4.2 million of expected insurance recoveries recorded during the second quarter, including reimbursement related to earlier legal costs. That benefit should not be extrapolated as a permanent reduction in the expense base. The quarter also contained a noncash contingent-consideration revaluation and a gain on the Talphera investment. Product economics are easier to assess when these separate effects are identified. Source

The June report identified an impairment indicator for the KIMYRSA/ORBACTIV product group but concluded no impairment was required at that date. That is a specific warning about assumptions for part of the acquired portfolio, not a statement that the whole Melinta acquisition failed. The business response to watch is sales, pricing and cash contribution from those products. Source

Manufacturing and customer concentration also matter. The June filing reported a single FDA-approved source for each of DefenCath’s two active ingredients, alongside work on supply alternatives, and large customer concentrations. A qualified alternate finished-dose site improves resilience but does not make every component interchangeable. Supply interruption or a major customer’s narrower rollout could affect revenue faster than a new development program can compensate. Source

MINOCIN has a positive legal development: on June 8, 2026 the company reported an appellate decision affirming the infringement judgment against Nexus and rejecting its invalidity challenge. That is distinct from other disputes and does not mark the end of all patent competition. The June report also retained an unremediated financial-control weakness involving review of significant non-routine transactions. Remediation needs demonstrated operation, not just a stated plan. Source Source

The acquired portfolio also requires a distinction between accounting performance and commercial performance. Amortization of acquired intangibles can depress GAAP earnings without a same-period cash payment, whereas a decline in the underlying product economics can affect both future cash and the recoverability of the asset. Excluding amortization from an adjusted measure does not remove the need to examine whether the original purchase price earns an adequate return. Conversely, a quarterly fair-value change in contingent consideration is not evidence that the corresponding cash payment occurred. Reading product sales, operating spending, cash flow and acquisition-related notes together avoids both mistakes. SEC filing

12 What to watch next, and the investment question

Third-quarter results were released on November 12, with a corporate-update call that day, showing $54.5 million of revenue and grant income, a $14.7 million net loss and $3.1 million of adjusted EBITDA; the company kept 2026 revenue guidance and suspended its 2027 DefenCath revenue guidance, expecting a new outlook in early 2027. The Heron closing is expected in the first quarter of 2027 and the REZZAYO prophylaxis target action falls in the same quarter. Also on that call, chairman and chief executive Joseph Todisco said he was cautiously optimistic about reaching a DefenCath Medicare Advantage agreement before the end of 2026, with no agreement announced. Q3 2026 results Form 8-K exhibit 99.1

The first full reporting period after the July 1 reimbursement change was the third quarter, reported on November 12, 2026; the next checkpoint is the fourth quarter and the 2027 outlook the company has said it will give in early 2027. The natural comparison starts with management’s reduced second-half revenue assumptions, then asks whether actual price, use and collections support them. Missing an extrapolation of first-half sales is not the same thing as missing the company’s stated annual outlook. A cut to that outlook, however, would be a materially different signal. Source Source

The clinical calendar has separate clocks. Additional ReSPECT data are expected in the fourth quarter of 2026 and DefenCath two-year real-world data in November, according to the September presentation. The REZZAYO application runs on its own FDA clock, with a PDUFA target action date in the first quarter of 2027. DefenCath’s TPN data were expected in 2028 in the same presentation, so that program had been presented as a longer-term option rather than an immediate catalyst; on the November 12, 2026 call, furnished on Form 8-K on November 16, management said the Phase 3 study was enrolling meaningfully behind its original timelines and that it is evaluating alternative paths to approval with the FDA if enrollment does not accelerate in the next one to two months, with a decision before the next quarterly call. Source Call transcript

For each update, the relevant question is what would actually change the economic case. Stronger infection-prevention evidence would support customer discussions, but net pricing still needs to produce acceptable margins. Positive regulatory progress would reduce uncertainty, but successful approval would also trigger milestones and require commercial execution. An increase in unrestricted cash would support flexibility only after rebate and collateral obligations are understood.

The central red flags are a price reset accompanied by loss of use, cash conversion sustained mainly by deferred customer payments, weaker contribution from acquired products, and a regulatory timetable that becomes less concrete while spending rises. None needs a technical stock-price forecast to matter. They describe ways in which the business could fail to turn approved products and clinical progress into durable cash generation.

CorMedix’s case rests on an existing cash-generating platform with a difficult reimbursement transition and an additional regulatory opportunity. The strength is that it enters this period with meaningful resources and marketed products. The unresolved test is how much recurring profit remains after the new economics, obligations and growth spending. That is the question the next sales, balance-sheet and clinical updates need to answer; it is not a recommendation to buy or sell.

Merlintrader Health Score · $CRMD

3.20out of 5
Financial resources · 30%3.5

$355.2 million of cash at September 30, 2026 and $218.3 million of nine-month operating cash flow, but a $14.7 million third-quarter net loss, including $11.5 million of non-cash contingent-consideration remeasurement, in the first full quarter after the DefenCath reimbursement change, against $145 million payable in cash for the Heron assets, $75 million drawn on a new $150 million Pharmakon facility and a $150 million convertible due in 2030. The acquired business brings roughly $150 million of trailing product revenue, but the leverage rises before any synergy arrives.

Catalysts · 30%3.5

Dated checkpoints now stack up: third-quarter results were released on November 12, 2026; the Heron closing is expected in the first quarter of 2027 subject to stockholder and antitrust clearance, the DefenCath post-TDAPA add-on from the first quarter of 2027, and the REZZAYO prophylaxis target action in the same window.

Capital allocation · 20%2.5

14,583,333 new shares, about 18% of the 79,537,626 outstanding at November 9, 2026 (third-quarter Form 10-Q), are payable to Heron at a fixed $105 million ÷ $7.20 per share, regardless of where the stock trades before closing. Buybacks, convertibles and equity awards remain outstanding alongside that issuance.

Trading liquidity · 10%3.0

Median daily volume was about 1.1 million shares (average about 1.5 million) over the 30 regular sessions to November 6, 2026. Nasdaq historical data

Operating execution · 10%3.0

The first post-TDAPA quarter brought $17.2 million of DefenCath net revenue, including a $5.0 million favorable estimate change, and a net loss; the company kept 2026 revenue guidance but suspended its 2027 DefenCath guidance. Integrating four acquired brands across hospital, surgery-center and infusion call points is the next test; on the November 12 call management also said the DefenCath TPN Phase 3 study was enrolling well behind its original timelines.

Reassessed November 12, 2026, after the third-quarter results: operating execution lowered from 3.5 to 3.0 for the third-quarter net loss and the suspension of 2027 DefenCath revenue guidance; the other four pillars are as assessed on November 10, when the overall score was 3.25. Reassessed November 16, 2026 against the call transcript furnished on Form 8-K on November 16: the slower TPN enrollment and the pending Medicare Advantage contracting are reflected in the 3.0 operating-execution score. Weighted calculation: 3.5×30% + 3.5×30% + 2.5×20% + 3.0×10% + 3.0×10% = 1.05 + 1.05 + 0.50 + 0.30 + 0.30 = 3.20. This describes financial and operational robustness over twelve to eighteen months, not an investment recommendation.

Red flags

  • The September 30 figures released on November 12, including $355.2 million of cash, are unaudited and not a current balance; the latest filed audited statements are for 2025.
  • Previously issued 2027 DefenCath revenue guidance was suspended on November 12 after CMS reimbursement changes, and third-quarter DefenCath revenue included a $5.0 million favorable change in a sales-allowance estimate.
  • The Heron transaction is signed, not closed: it needs Heron stockholder approval and antitrust clearance, and is expected to close in the first quarter of 2027.
  • Synergies of $45–60 million and pro forma revenue of $465–490 million are company estimates, not reported results.
  • The 14,583,333 shares are fixed in number and will not be adjusted for CorMedix’s share price before closing.
  • The 2027 trajectory the company has described anticipates a lower add-on rate in the second quarter of 2027 than in the first, before it rises again in the third and fourth quarters; that path is a company expectation. CorMedix says third-party projections, including those of a large dialysis organization, are not guidance provided or endorsed by the company, and actual quarterly rates depend on how CMS applies utilization data.
  • REZZAYO filing acceptance and Priority Review do not assure approval.
  • The DefenCath TPN Phase 3 study is enrolling meaningfully behind its original timelines; management said on November 12 that it may pursue an alternative approval path with the FDA and expects to decide before its next quarterly call.

CRMD Stock FAQ: CorMedix Inc. Questions Answered

When is the next CorMedix CRMD stock catalyst?

CorMedix released third-quarter 2026 results on November 12, 2026, and held a corporate-update call that day; it expects to give a new 2027 DefenCath outlook in early 2027. Third-quarter results. It held a conference call on the Heron asset purchase on November 9, 2026, and expects the deal to close in the first quarter of 2027, subject to Heron stockholder approval and antitrust clearance. Heron acquisition announcement. The REZZAYO prophylaxis application has an FDA target action window in the same quarter. REZZAYO review. The September 2026 presentation also points to additional ReSPECT data in Q4 2026 and two-year DefenCath real-world results in November, without exact dates. Company presentation.

Is CorMedix’s REZZAYO FDA approved for fungal prophylaxis?

No: as of November 12, 2026, REZZAYO’s proposed fungal-prophylaxis indication remained under review, with Priority Review acceptance announced October 19 and a Q1 2027 target action window. The application concerns adults undergoing allogeneic hematopoietic stem-cell transplantation; the existing candidemia treatment indication is different. Application and existing indication.

How much cash does CorMedix have, and how long will it last?

CorMedix reported unaudited cash and cash equivalents of $355.2 million at September 30, 2026, excluding restricted cash, up from $256.692 million at June 30. Nine-month operations generated $218.3 million, and the company says resources are sufficient for at least twelve months from the issuance of its third-quarter Form 10-Q. Against that, the Heron purchase requires $145 million of cash at closing, funded partly by drawing $75 million of a new $150 million Pharmakon term loan; the company has not published a post-closing cash figure. September 30 cash position. September 30 balance sheet and Form 10-Q. Cash and loan terms of the Heron transaction.

Is CRMD stock at risk of dilution from the Heron deal?

Yes: the Heron purchase includes 14,583,333 new CorMedix shares, about 18% of the 79,537,626 outstanding at November 9, 2026, according to the third-quarter Form 10-Q. The number was fixed by dividing $105 million by $7.20 a share and is not adjusted for share-price moves before closing. Convertible debt of $150 million due in 2030, stock awards and buybacks of $17.484 million in the first nine months of 2026 remain part of the per-share picture. Share consideration and terms. Existing capital structure.

When does CorMedix report earnings?

CorMedix released third-quarter 2026 results on November 12, 2026, and held a corporate-update conference call that day: revenue and grant income of $54.5 million, a net loss of $14.7 million and 2026 revenue guidance of $325–345 million maintained. It has not announced a date for full-year 2026 results. Third-quarter results, November 12. Company update, November 2. Official event calendar.

What does CorMedix do?

CorMedix develops and markets medicines to prevent and treat serious infections. DefenCath is its catheter-lock product for eligible hemodialysis patients; its broader commercial portfolio includes the antifungal REZZAYO, with an additional prophylaxis indication under regulatory review. Commercial business. REZZAYO development.

Is CorMedix profitable?

Not in the latest quarter: CorMedix reported a net loss of $14.7 million, or $0.19 per share, on $54.5 million of revenue and grant income for the quarter ended September 30, 2026. It was the first full quarter after the July 1 change in DefenCath reimbursement; the loss included $11.5 million of non-cash contingent-consideration remeasurement, and adjusted EBITDA was $3.1 million. Nine-month net income was $49.867 million. In the quarter ended June 30 it had reported $25.988 million of net income on $101.931 million. Third-quarter results. Quarterly results and reimbursement.

What is CorMedix buying from Heron Therapeutics, and on what terms?

CorMedix is buying substantially all of Heron’s assets for $145 million in cash and 14,583,333 shares. The four products — ZYNRELEF, APONVIE, CINVANTI and SUSTOL — carry about $150 million of trailing twelve-month net product revenue. Heron can also receive up to $55 million in earn-outs: $25 million if ZYNRELEF net sales reach $65 million in 2028 and a further $30 million if they reach $95 million in 2028, plus a 5% royalty on combined CINVANTI, SUSTOL and licensed-product sales above $25 million in 2027–2029. Terms of the asset purchase agreement.

Primary sources

Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $CRMD or any other security.

Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.

Biotechnology and healthcare companies carry binary risk. Clinical trials fail, regulatory decisions go against the applicant, approval does not guarantee commercial uptake, and development-stage companies frequently raise equity at whatever price the market will bear. A single readout can change the value of the business overnight in either direction, and companies at this stage can lose all of their value. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.